Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

SPARC's projected revenue growth above last year's levels could present an attractive investment option. If this increase is confirmed by other strong fundamental signals, investors might consider it a positive opportunity to capitalize on the company's rising financial performance and potential long-term gains.

Financial Ratios:

currentRatio 0.000000
forwardPE 2.514079
debtToEquity 0.000000
earningsGrowth 0.000000
revenueGrowth -0.433000
grossMargins 0.412460
operatingMargins -7.007100
trailingEps -8.250000
forwardEps 55.400000

Sun Pharma Advanced Research Company Limited's low earnings and revenue growth suggest that the company may see declining profits. This indicates potential financial challenges ahead, and could lead to a more cautious outlook from investors.

Price projections:

Price projections for SPARC
Price projections for SPARC



Recommendation changes over time:

Recommendations trend for SPARC
Recommendations trend for SPARC


Analysts have shown a buy bias for Sun Pharma Advanced Research Company Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Sun Pharma Advanced Research Company Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.